This article is more than 5 years old. Information may no longer be current.

Endovascular aneurysm sealing system linked to positive outcomes at 2 years

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An endovascular aneurysm sealing system was associated with positive mortality and endoleak outcomes at 2 years, according to findings presented at VEITHsymposium.

The system (Nellix EVAS System, Endologix) is a new type of therapy for patients with abdominal aortic aneurysms designed to seal the entire sac, according to a press release from the company.

Andrew Holden, MBChB , associate professor of radiology at Auckland City Hospital in New Zealand, presented 2-year data from the company’s EVAS FORWARD registry of 300 patients, 37% of whom had complex anatomies, treated with the system in Europe and New Zealand.

According to the 2-year results, 98.1% of patients had freedom from any persistent endoleaks and there were no secondary interventions for Type II endoleaks. Additionally, there was a 97% rate of freedom from aneurysm-related mortality and a 99% rate of freedom from CV mortality.

The rate of persistent endoleak at last follow-up was 1.8% (type Ia, 0.4%; type Ib, 0.4%; type II, 0.7%; type III, 0%; unknown type, 0.4%), according to Holden.

Freedom from type Ia endoleak (P = .0008) and freedom from secondary intervention (P = .0066) were more common in those who had a procedure within the indications for use than in those who did not, Holden said.

“The 2-year results from the EVAS FORWARD global registry confirm the significant potential for EVAS with Nellix to treat a broad range of patients and provide excellent results, especially within the indications for use,” Holden said in the release. “In addition, the continued low rates of aneurysm and [CV]-related mortality suggest that EVAS with Nellix may provide additional benefits beyond traditional EVAR.” – by Cassie Homer and Erik Swain

Reference:

Holden A, et al. Session 56: More New and Improved Devices for EVAR and EVAS. Presented at: VEITHsymposium; Nov. 15-19, 2016; New York.

Disclosure: Holden reports serving as a clinical investigator and on a medical advisory board for Endologix.